Search Results - "Mencher, Simon K."

  • Showing 1 - 5 results of 5
Refine Results
  1. 1

    Natura-Alpha Targets Forkhead Box M1 and Inhibits Androgen-Dependent and -Independent Prostate Cancer Growth and Invasion by YIRONG LI, LIGR, Martin, MENCHER, Simon K, LEPOR, Hebert, WANG, Long G, LEE, Peng, MCCARRON, James P, DANIELS, Garrett, ZHANG, David, XIN ZHAO, FEI YE, JINHUA WANG, XIAOMEI LIU, OSMAN, Iman

    Published in Clinical cancer research (01-07-2011)
    “…The development of new effective therapeutic agents with minimal side effects for prostate cancer (PC) treatment is much needed. Indirubin, an active molecule…”
    Get full text
    Journal Article
  2. 2

    Interaction of a small molecule Natura-α and STAT3-SH2 domain to block Y705 phosphorylation and inhibit lupus nephritis by Chiao, J.W., Melikian, Maxime, Han, Liying, Xue, Chengsen, Tsao, Allen, Wang, Luxi, Mencher, Simon K., Fallon, John, Solangi, Karim, Bertho, Gildas, Wang, Long G.

    Published in Biochemical pharmacology (01-01-2016)
    “…Natura-α binds SH2 domain of STAT3, forms H-bonds with Glu594 and Arg609, preventing Y705 phosphorylation. The efficacy was evaluated in lupus mice, Natura-α…”
    Get full text
    Journal Article
  3. 3

    Treatment of collagen-induced arthritis by Natura-α via regulation of Th-1/Th-17 responses by Glatigny, Simon, Blaton, Marie-Agnès, Mencher, Simon K, Mistou, Sylvie, Lucas, Bruno, Fournier, Catherine, Wang, Long G, Chiocchia, Gilles

    Published in European journal of immunology (01-02-2010)
    “…Cytokines and CD4⁺ Th cells play a crucial role in the pathogenesis of rheumatoid arthritis. Among the Th populations, Th-1 and Th-17 have been described as…”
    Get full text
    Journal Article
  4. 4

    Promiscuous drugs compared to selective drugs (promiscuity can be a virtue) by Mencher, Simon K, Wang, Long G

    Published in BMC clinical pharmacology (26-04-2005)
    “…The word selectivity describes a drug's ability to affect a particular cell population in preference to others. As part of the current state of art in the…”
    Get full text
    Journal Article
  5. 5

    The biological basis for the use of an anti-androgen and a 5-alpha-reductase inhibitor in the treatment of recurrent prostate cancer: Case report and review by Wang, Long G, Mencher, Simon K, McCarron, J P, Ferrari, Anna C

    Published in Oncology reports (01-06-2004)
    “…Although many prostate cancer cases relapse to a hormone-insensitive state, endocrine therapy involving androgen depletion by orchiectomy or by treatment with…”
    Get more information
    Journal Article